In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Action Pharma A/S

Latest From Action Pharma A/S

Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy

The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.

BioPharmaceutical Denmark

Alliance Shift: Private Biotechs See Up-Front Cash Boost In 2012

Biopharma alliance volume has dropped over the past five years, but in 2012, privately held out-licensers averaged better up-fronts than their publicly traded counterparts, according to Elsevier’s Strategic Transactions.

BioPharmaceutical Deals

Deals in Depth: May 2012

In one of several large up-front deals it’s done in the past few years, Abbott paid $110 million for Action’s kidney injury candidate. Agilent bought cancer diagnostics firm Dako for $2.2 billion. And both biopharma and medical device financing went up in May compared with April.

BioPharmaceutical Medical Device

Kidney Disease: A Price-Sensitive Market But A Bundle Of Opportunity

Medicare’s bundling policy for drugs and services in dialysis has turned on the pricing pressure in kidney disease. The cost containment policies have negatively impacted sales of some drugs and put a spotlight on growing costs in chronic kidney disease and end-stage renal disease. Nonetheless, there is plenty of opportunity for new drugs that can address the area’s unmet medical need, especially if they can help to reduce broader health care spending. That will require demonstrating value to payors and providers, however, particularly for drugs that treat secondary conditions associated with kidney disease.

BioPharmaceutical Pricing Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals